Activation of 4-1BB on liver myeloid cells triggers hepatitis via an interleukin-27 dependent pathway.

CONCLUSIONS: 4-1BB agonist antibodies trigger hepatitis via activation and expansion of interleukin-27-producing liver Kupffer cells and monocytes. Co-administration of CTLA-4 and/or CCR2 blockade may minimize hepatitis, but yield equal or greater antitumor immunity.
PMID: 29301830 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 4, 2018 Category: Cancer & Oncology Authors: Bartkowiak T, Jaiswal AR, Ager CR, Chin R, Chen CH, Budhani P, Ai M, Reilley MJ, Sebastian MM, Hong DS, Curran MA Tags: Clin Cancer Res Source Type: research